Moclobemide and clomipramine in endogenous depression. A randomized clinical trial

C Koczkas; P Holm; A Karlsson; A Nagy; E Ose; H Pétursson; L Ulverås; O Wenedikter

doi:10.1111/j.1600-0447.1989.tb10298.x

Moclobemide and clomipramine in endogenous depression. A randomized clinical trial

Acta Psychiatr Scand. 1989 Jun;79(6):523-9. doi: 10.1111/j.1600-0447.1989.tb10298.x.

Authors

C Koczkas¹, P Holm, A Karlsson, A Nagy, E Ose, H Pétursson, L Ulverås, O Wenedikter

Affiliation

¹ Danderyd Hospital, Sweden.

PMID: 2669440
DOI: 10.1111/j.1600-0447.1989.tb10298.x

Abstract

The purpose of this study was to compare moclobemide and clomipramine in endogenous depression according to the Newcastle II classification. Sixty-two patients were allocated to either 300 mg moclobemide or 150 mg clomipramine, both given in 3 daily doses. Improvements occurred over time but differences between treatments were never statistically significant. Dizziness, tremor and anticholinergic symptoms were significantly more frequent with clomipramine.

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial

MeSH terms

Adult
Aged
Antidepressive Agents / adverse effects
Antidepressive Agents / therapeutic use*
Benzamides / adverse effects
Benzamides / therapeutic use*
Clinical Trials as Topic
Clomipramine / adverse effects
Clomipramine / therapeutic use*
Depressive Disorder / drug therapy*
Depressive Disorder / psychology
Double-Blind Method
Female
Humans
Male
Middle Aged
Moclobemide
Psychiatric Status Rating Scales
Random Allocation

Substances

Antidepressive Agents
Benzamides
Clomipramine
Moclobemide